Acromegaly

Guideline

Table

Appendix

Full Guideline: Acromegaly: An Endocrine Society Clinical Practice Guideline

JCEM November 2014
Laurence Katznelson, Edward R. Laws, Jr., Shlomo Melmed, Mark E. Molitch, Mohammad Hassan Murad, Andrea Utz, John A. H. Wass

Co-Sponsoring Organization: European Society of Endocrinology

Objective:

The aim was to formulate clinical practice guidelines for acromegaly.

Background:

Acromegaly is a chronic disorder caused by GH hypersecretion. GH circulates and stimulates production of IGF-1 from the liver and systemic tissues; IGF-1 in large part mediates the somatic and metabolic effects of GH. Hypersecretion of GH leads to excess production of IGF-1, leading to a multisystem disease characterized by somatic overgrowth, multiple comorbidities, premature mortality, and physical disfigurement. A multidisciplinary approach is critical for the management of acromegaly.

Using an evidence-based approach, this acromegaly guideline addresses important clinical issues regarding the evaluation and management of acromegaly, including:

• the appropriate biochemical assessment
• a therapeutic algorithm, including use of medical monotherapy or combination therapy
• and management during pregnancy

Read the Full Guideline